denkapparat Operations GmbH Buys Shares of 5,908 Hologic, Inc. (NASDAQ:HOLX)

denkapparat Operations GmbH purchased a new position in shares of Hologic, Inc. (NASDAQ:HOLX) in the fourth quarter, Holdings Channel.com reports. The institutional investor purchased 5,908 shares of the medical equipment provider’s stock, valued at approximately $426,000.

A number of other large investors also recently bought and sold shares of HOLX. FMR LLC lifted its holdings in Hologic by 64.0% during the 3rd quarter. FMR LLC now owns 5,572,545 shares of the medical equipment provider’s stock valued at $453,940,000 after buying an additional 2,174,093 shares in the last quarter. Norges Bank purchased a new position in shares of Hologic during the fourth quarter worth approximately $133,414,000. Boston Partners raised its stake in shares of Hologic by 81.0% during the fourth quarter. Boston Partners now owns 3,580,519 shares of the medical equipment provider’s stock valued at $257,959,000 after acquiring an additional 1,602,463 shares in the last quarter. Nordea Investment Management AB boosted its holdings in shares of Hologic by 32.7% in the fourth quarter. Nordea Investment Management AB now owns 2,213,607 shares of the medical equipment provider’s stock valued at $159,911,000 after purchasing an additional 544,889 shares during the period. Finally, Raymond James Financial Inc. purchased a new position in Hologic during the 4th quarter worth $27,007,000. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Hologic Stock Performance

Shares of Hologic stock opened at $62.32 on Friday. The business has a 50-day moving average of $65.41 and a 200 day moving average of $73.50. The stock has a market capitalization of $13.98 billion, a price-to-earnings ratio of 19.66, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97. Hologic, Inc. has a 12 month low of $60.34 and a 12 month high of $84.67. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78.

Hologic (NASDAQ:HOLX) last issued its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. As a group, sell-side analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on HOLX. Royal Bank of Canada dropped their target price on shares of Hologic from $88.00 to $85.00 and set a “sector perform” rating on the stock in a report on Thursday, February 6th. Needham & Company LLC downgraded shares of Hologic from a “buy” rating to a “hold” rating and set a $90.00 price objective for the company. in a research note on Monday, February 3rd. Raymond James reaffirmed an “outperform” rating and set a $90.00 target price (down previously from $95.00) on shares of Hologic in a research report on Thursday, February 6th. Leerink Partners lowered Hologic from an “outperform” rating to a “market perform” rating and reduced their price target for the stock from $80.00 to $75.00 in a research report on Thursday, February 6th. Finally, Argus downgraded Hologic from a “buy” rating to a “hold” rating in a research report on Monday, March 3rd. Eleven research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $84.62.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.